A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ADEFOVIR DIPIVOXIL WHEN ADDED TO STANDARD ANTIRETROVIRAL THERAPY FOR THE TREATMENT OF HIV-INFECTED PATIENTS WITH CD4 CELL COUNTS >= 200/MM3: